Compass Pathways (CMPS) Expected to Announce Quarterly Earnings on Thursday

Compass Pathways (NASDAQ:CMPS) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 2:00 AM ET.

Compass Pathways Stock Up 10.7%

Shares of Compass Pathways stock opened at $8.45 on Thursday. The company has a market cap of $811.37 million, a P/E ratio of -3.11 and a beta of 1.92. Compass Pathways has a 52-week low of $2.25 and a 52-week high of $8.90. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55. The firm’s 50 day moving average price is $6.80 and its 200-day moving average price is $5.91.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CMPS shares. Royal Bank Of Canada boosted their price target on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a research note on Wednesday, January 21st. Morgan Stanley upped their price objective on Compass Pathways from $11.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday. Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Finally, Compass Point set a $15.00 target price on Compass Pathways in a research report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.56.

Compass Pathways News Roundup

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: Positive Phase III topline: COMP360 met its primary endpoint in a late‑stage trial (statistically significant symptom reduction, rapid onset and durability through later weeks), strengthening the drug’s clinical and regulatory outlook and lifting sector sentiment. Read More.
• Positive Sentiment: Analyst support: Analysts have an average rating of “Moderate Buy,” which can sustain inflows and provide selling-pressure resistance after the clinical win. Read More.
• Neutral Sentiment: Options and trading flows: Unusually large call option volume suggests short-term speculative/bullish positioning; this can amplify intraday moves but doesn’t change fundamentals.
• Neutral Sentiment: Confusing short‑interest report: recent data showing zero shares and NaN changes appears unreliable and offers no clear signal to investors; ignore until clarified by a trustworthy data release.
• Negative Sentiment: Equity raise and dilution risk: Compass launched a proposed $150M public offering to fund development and commercialization. The raise — and reporting that the offering price is deeply discounted to recent levels — prompted pre‑market weakness and creates near‑term dilution that can cap upside until proceeds are deployed. Read More.

Institutional Trading of Compass Pathways

A number of institutional investors have recently made changes to their positions in the company. Royal Bank of Canada increased its position in shares of Compass Pathways by 49.8% during the first quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock worth $256,000 after purchasing an additional 29,733 shares in the last quarter. Acadian Asset Management LLC grew its stake in Compass Pathways by 42.0% during the 1st quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock valued at $686,000 after acquiring an additional 71,112 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in Compass Pathways by 47.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after acquiring an additional 1,350,698 shares during the last quarter. Balyasny Asset Management L.P. lifted its stake in Compass Pathways by 38.0% in the 2nd quarter. Balyasny Asset Management L.P. now owns 854,840 shares of the company’s stock worth $2,394,000 after purchasing an additional 235,345 shares in the last quarter. Finally, Northeast Financial Consultants Inc acquired a new position in shares of Compass Pathways during the 2nd quarter worth approximately $59,000. 46.19% of the stock is owned by institutional investors and hedge funds.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.